AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 284: H309-H316, 2003. First published September 19, 2002; doi:10.1152/ajpheart.00453.2002
0363-6135/03 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/1/H309    most recent
00453.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carter, R. W.
Right arrow Articles by Kanagy, N. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carter, R. W.
Right arrow Articles by Kanagy, N. L.
Vol. 284, Issue 1, H309-H316, January 2003

Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension

Rebecca W. Carter and Nancy L. Kanagy

Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131-5218


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS AND MATERIALS
RESULTS
DISCUSSION
REFERENCES

PKC augments calcium sensitivity in spontaneously hypertensive rats and contributes to alpha 2-adrenergic receptor (AR) contraction in rabbit saphenous vein. We showed previously that denuded aortic rings from Nomega -nitro-L-arginine-treated hypertensive rats (LHR) contract more to CaCl2 and to the alpha 2-AR agonist UK-14304 than do rings from normotensive rats (NR). We hypothesized that enhanced PKC activity or a change in PKC isoform contributes to augmented calcium sensitivity and enhanced alpha 2-AR contraction in LHR aorta. Current studies demonstrate that non-isoform-specific PKC inhibitors reduced UK-14304 contraction in both NR and LHR aorta. However, the calcium-dependent PKC inhibitor Gö-6976 only attenuated contraction in LHR aorta. Additionally, UK-14304 translocated PKC-delta to the membrane in NR aorta, whereas PKC-alpha was translocated to the membrane in LHR aorta. Finally, in ionomycin-permeabilized aorta Gö-6976 eliminated enhanced basal and augmented alpha 2-AR-stimulated calcium sensitivity in LHR aorta but did not affect NR contraction. Together, these data suggest that PKC-alpha contributes to augmented calcium sensitivity and alpha 2-AR reactivity after chronic nitric oxide synthase inhibition hypertension.

nitric oxide; alpha 2-adrenergic receptors; protein kinase C; vascular smooth muscle; calcium sensitivity


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS AND MATERIALS
RESULTS
DISCUSSION
REFERENCES

alpha 2-ADRENERGIC RECEPTORS (AR) are Gi protein-coupled receptors present within the vasculature on both the endothelium and the vascular smooth muscle (2). On stimulation, endothelial receptors activate nitric oxide (NO) synthase (NOS) and trigger NO release whereas vascular smooth muscle receptors promote vasoconstriction (1, 2, 13, 14). In vivo, the endothelial and vascular receptors work in concert to provide an appropriate response to catecholamines. However, damage to the endothelium results in enhanced vasoreactivity to alpha 2-AR stimulation. We showed previously (14, 23) that vascular reactivity to CaCl2 and to the alpha 2-AR agonist UK-14304 is augmented in denuded aorta and mesenteric arteries from chronically NOS-inhibited hypertensive rats [Nomega -nitro-L-arginine (L-NNA) hypertensive rats; LHR]. These data suggest an altered vascular smooth muscle response to these stimuli in this model of hypertension. However, we have not identified the mechanism(s) for this increased vasoreactivity.

Although we have determined that L-type calcium channels, tyrosine kinases, extracellular signal-regulated kinase, and Rho-associated kinase contribute to alpha 2-AR contraction, none of these is responsible for increased calcium sensitivity or augmented alpha 2-AR contraction in LHR (7, 13, 23). Therefore, other kinases linked to both alpha 2-AR and calcium sensitivity may be affected in NOS inhibition hypertension.

PKC is a family of signaling molecules with 11 isoforms encoded by 10 genes and divided into 3 subfamilies based on differences in regulatory domains (21). The conventional or calcium-dependent isoforms, alpha , beta , and gamma , have both calcium-binding and lipid-binding domains. The novel or calcium-independent isoforms, delta , epsilon , eta , and theta , contain a lipid-binding domain but no calcium-binding domain. The atypical isoforms, lambda , iota , and zeta , contain neither a calcium-binding nor a lipid-binding domain (21). Many PKC isoforms, including alpha , delta , epsilon , eta , and zeta , are present in vascular smooth muscle (21) and participate in contraction by augmenting calcium sensitivity (5, 8, 9, 11, 24) or by increasing the open probability of L-type calcium channels (4, 24). In alpha 2-AR contraction, Aburto et al. (1) showed that the PKC inhibitors calphostin C and staurosporine inhibit alpha 2-AR contraction in rabbit saphenous vein, suggesting that PKC contributes to the contraction. Additionally, Kanashiro et al. (15) demonstrated that PKC-alpha is activated by phenylephrine in the aorta from pregnant rats after NOS inhibition. Together, these data indicate that PKC may play a role in augmented vasoreactivity to alpha 2-AR and CaCl2 in LHR aorta.

The goal of this study was to evaluate the contribution of PKC to alpha 2-AR contraction as a potential mechanism of augmented calcium sensitivity and enhanced alpha 2-AR contraction after NOS inhibition hypertension. We hypothesized that enhanced PKC activity or recruitment of additional PKC isoforms augments alpha 2-AR contraction and calcium sensitivity after chronic in vivo NOS inhibition.


    METHODS AND MATERIALS
TOP
ABSTRACT
INTRODUCTION
METHODS AND MATERIALS
RESULTS
DISCUSSION
REFERENCES

Animals. Male Sprague-Dawley rats (250-300 g) drank tap water containing 0.5 g/l L-NNA (L-NNA hypertensive rats; LHR) or vehicle (normotensive rats; NR) for 14 days. Blood pressures (tail cuff; IITC, Woodland Hills, CA) and animal weight were measured on days 0, 7, and 14. Mean systolic blood pressures on day 14 were 136 ± 3 and 201 ± 2 mmHg for NR and LHR, respectively. After the 14-day treatment period, animals were anesthetized with pentobarbital sodium (60 mg/kg ip). Thoracic aorta were removed and placed in ice-cold physiological saline solution (PSS; in mM: 130 NaCl, 4.7 KCl, 1.18 KH2PO4, 1.17 MgSO4 · 7H2O, 14.9 NaHCO3, 5.5 dextrose, 0.026 CaNa2-EDTA, and 1.6 CaCl3, pH 7.3). Vessels were cleaned of visible fat, cut into 4-mm rings, and denuded of endothelium with the tip of closed sharp forceps.

Calcium-tension measurements. Endothelium-denuded aortic rings were cut into helical strips and incubated overnight at 4°C in PSS containing fura 2-AM (2 µM), cremophor-EL (0.2 µl/ml), and pluronic acid (0.02%). After incubation, strip ends were clamped with metal clips (Kent Scientific) and the clips were affixed to stainless steel hooks attached to a myograph (Kent Scientific) and placed in a heated water bath mounted in the base of a Nikon Diaphot 300 microscope fitted with a ×10 Nikon fluor objective. Strips were perfused with PSS maintained at 37°C and bubbled with 95% O2-5% CO2 for 60 min. During the equilibration period, strips were stretched to 2,000-mg passive tension to achieve maximal active tension generation (appropriate tension determined by length-tension curves; data not shown). Indomethacin (1 µM) was added to the perfusate in the final 30 min of equilibration. Strips were exposed to a single concentration of phenylephrine (0.1 µM) to determine viability. Lack of relaxation to acetylcholine (1 µM) in phenylephrine-contracted rings was used to check for endothelium removal, and strips were washed until no active tension remained. Strips were exposed to cumulative concentrations of the alpha 2-AR agonist UK-14304 (10-8-10-5 M). Tension was recorded on a polygraph (Gould Instruments, Harvard, MA). Vessels were excited with alternate 340 and 380 nm at a period of 0.3 Hz. Emissions were collected at 510 nm and analyzed with MetaFluor software (Universal Imaging). Data are expressed as the mean 340- to 380-nm ratio. Strips were again washed until no active tension remained, and PSS was replaced with calcium-free PSS. Strips were permeabilized with the calcium ionophore ionomycin (1.5 µM), after which CaCl2 (0.8 or 1.6 mM) was added to the bath. Calcium contraction was allowed to plateau, and the strips were then exposed to UK-14304 (10 µM).

Contractile studies. Endothelium-denuded aortic rings were attached to a force transducer (Grass Instruments, Quincy, MA) with stainless steel hooks, and generated tension was recorded on a polygraph (Gould Instruments). Two rings, one NR and one LHR, were placed in a temperature-controlled, water-jacketed tissue bath containing 37°C PSS bubbled with 95% O2-5% CO2. Rings were stretched to 2,500-mg passive tension and allowed to equilibrate for 60 min. Indomethacin (1 µM) was added in the final 30 min. Rings were considered viable if at least 1,000-mg active tension was generated after exposure to a single concentration of phenylephrine (0.1 µM). Lack of relaxation to acetylcholine (1 µM) in phenylephrine-contracted rings was used to check for endothelium removal. Rings were washed until no active tension remained (30-60 min) and then exposed to cumulative concentrations of UK-14304 (10-9-10-5 M) in the presence or absence of increasing concentrations of PKC inhibitors. Time controls were performed with each experiment, and data were not reported if differences were apparent in time controls.

Three separate PKC inhibitors were used. Calphostin C and chelerythrine chloride are unique non-isoform-specific PKC inhibitors. Calphostin is an inhibitor of the PKC regulatory subunit, whereas chelerythrine is an inhibitor of the ATP binding site (9, 16). Therefore, these non-isoform-specific PKC inhibitors should attenuate the activity of all PKC isoforms. The third PKC inhibitor used, Gö-6976, inhibits the ATP binding site of conventional PKC molecule and therefore should only attenuate Ca2+-dependent PKC activity (37). In separate experiments, viable rings were incubated for 30 min with one of the PKC inhibitors or vehicle (DMSO). After incubation, calcium-containing PSS was replaced with calcium-free PSS in the continued presence of the inhibitor or vehicle. Ionomycin (1.5 µM) was added to the bath to permeabilize vascular smooth muscle cells. Tension was allowed to stabilize, and then 0.4 or 0.8 mM CaCl2 was added. Contraction in permeabilized segments was allowed to reach a steady state, after which UK-14304 (10-8-10-5 M) was added to the bath to evaluate basal calcium sensitivity and alpha 2-AR contraction independent of increases in intracellular calcium.

There is some evidence that high concentrations of intracellular calcium can activate PKC-alpha (19), and we found that in 0.8 mM CaCl2 Gö-6976 attenuated CaCl2 contraction in both NR and LHR aorta (data not shown). To avoid direct CaCl2 stimulation of PKC-alpha in experiments testing PKC-alpha effect on calcium sensitivity, we used the lowest concentration of CaCl2 that consistently contracted both NR and LHR aorta, 0.4 mM CaCl2.

PKC activity. Rings were hung in water-jacketed tissue baths as for contractile experiments and equilibrated for 60 min. After equilibration, tissues were exposed to the alpha 2-AR agonist UK-14304 (10 µM). Exactly 10 min after agonist stimulation (appropriate activation time determined by time course study; data not shown), rings were removed from baths and placed in ice-cold homogenization buffer [in mM: 50 Tris · HCl, 1 DTT, 10 benzamidine, and 10 mM EGTA with complete protease inhibitor (Roche Mannheim), pH 7.5]. Homogenate was centrifuged at 13,000 g for 3 min at 4°C. The supernatant was removed and centrifuged at 100,000 g for 20 min. The supernatant (cytosolic fraction) was removed, and the pellet (membrane fraction) was resuspended in homogenization buffer plus 1% Triton X-100. Protein concentration of each fraction was determined with a modified Lowry method (Pierce). Inactive PKC is found in the cytosol and translocates to the membrane on activation; therefore, PKC activity can be estimated by the amount of PKC present in the membrane fraction versus the amount present in the cytosolic fraction.

For Western blot analysis, protein concentrations were normalized and samples were loaded into a 7.5% acrylamide gel for resolution with electrophoresis. Separated proteins were transferred onto polyvinylidene difluoride membranes and blocked 1 h with Tris-buffered saline containing 0.1% Tween 20, 5% milk, and 3% bovine serum albumin. Blots were incubated overnight at 4°C with anti-PKC-alpha or anti-PKC-delta (1:500), followed by secondary antibody for 1 h at room temperature (1:10,000) and developed with enhanced chemiluminescence reagents. Positive controls were also loaded. After analyses, blots were stained with Coomassie blue to ensure equivalent protein loading. Protein levels were compared by densitometric analysis with SigmaGel software (SPSS). Results are reported as the ratio of membrane to cytosolic PKC-alpha or PKC-delta .

For total PKC activity, 3 µg each of cytosolic and membrane protein were analyzed with a PKC activity assay kit (Amersham). Briefly, samples were incubated with 32P-labeled ATP and a PKC-specific substrate peptide (RKRTLRRL) for 15 min at 37°. Activity was measured as the total incorporation of [32P]ATP on the substrate, measured by scintillation counter. Results are reported as the ratio of membrane to cytosolic PKC activity.

Statistics. Data are reported as means ± SE and were analyzed with a two-way ANOVA. Post hoc tests were performed with Student-Newman-Keuls test. P values <= 0.05 are considered significant.

Materials. PKC-positive controls and antibodies were purchased from BD Biosciences. PKC activity assay kit and chemiluminescent reagents were purchased from Amersham. Fura 2-AM was purchased from Molecular Probes, Calphostin C, chelerythrine chloride, Gö-6976, and LY-294002 were purchased from BioMol Research Labs. All other reagents were purchased from Sigma-Aldrich.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS AND MATERIALS
RESULTS
DISCUSSION
REFERENCES

Enhanced calcium sensitivity in LHR aorta. To evaluate calcium sensitivity, concurrent calcium-tension measurements were generated with fura 2-AM-loaded aortic strips. Basal fluorescence was not different between NR and LHR aorta (mean 340-to-380 ratio: NR 0.69 ± 0.02, LHR 0.69 ± 0.03). Strips were then exposed to cumulative concentrations of UK-14304 (10-8-10-5 M). LHR strips were more sensitive to UK-14304 than NR strips; however, change in fluorescence was less in LHR than in NR, suggesting an increase in alpha 2-AR-induced calcium sensitivity (Fig. 1A). Similarly, CaCl2 (0.8 and 1.6 mM) produced a greater contraction with similar calcium increases in ionomycin-permeabilized LHR strips than in NR strips, suggesting augmented basal calcium sensitivity (Fig. 1B). To determine whether UK-14304 was capable of increasing intracellular calcium above that generated by CaCl2 in ionomycin-permeabilized strips, UK-14304 was added to the bath after contraction to CaCl2 had plateaued. Although UK-14304 increased tension, it did not change the 340-to-380 ratio (Table 1). These data suggest that in ionomycin-permeabilized vessels, UK-14304 does not change intracellular calcium concentrations, and they validate the use of this method to study basal and alpha 2-AR-stimulated calcium sensitivity.


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 1.   Nomega -nitro-L-arginine hypertensive rat (LHR) aorta contracts more to the alpha 2-adrenergic receptor (AR) agonist UK-14304 and to CaCl2 with the same or reduced increase in intracellular calcium concentration ([Ca2+]i). Fura 2-AM-loaded, endothelium-denuded normotensive rate (NR) and LHR thoracic aortic strips were used to generate consecutive cumulative concentration response curves to UK-14304 (10-8-10-5 M) while fluorescence (340- to 380-nm ratio) was measured (A). Additionally, ionomycin-permeabilized strips were exposed to 2 different concentrations of CaCl2 (0.8 and 1.6 mM; B). Each data point represents an increasing concentration of UK-14304 or CaCl2. * Statistically significant difference between NR and LHR; n = 7 (NR) and 5 (LHR).


                              
View this table:
[in this window]
[in a new window]
  		Table 1.   Effect of UK-14304 on NR and LHR aorta

Both NR and LHR aortic segments were adversely affected by overnight incubation with fura 2-AM, and overall fewer LHR strips were viable on testing the following day. To avoid the confounding problem of decreased viability of LHR strips, freshly isolated ionomycin-permeabilized aortic rings were also exposed to CaCl2, followed by cumulative concentrations of UK-14304. CaCl2 (0.8 mM) and UK-14304 (10-8-10-5 M) contracted LHR more than NR rings (Fig. 2, A and B), supporting the conclusion that there is enhanced basal and UK-14304-stimulated calcium sensitivity in LHR aorta.


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 2.   Ionomycin-permeabilized denuded aortic rings from LHR contract more to CaCl2 and to the alpha 2-AR agonist UK-14304 than NR rings. Aortic rings in calcium-free buffer were permeabilized with the calcium ionophore ionomycin (1.5 µM) and exposed to 0.8 mM CaCl2. The contraction was allowed to plateau (A), and the rings were then exposed to cumulative concentrations of UK-14304 (10-8-10-5 M; B). * Statistically significant difference between NR and LHR; n = 5.

Contribution of PKC to alpha 2-AR contraction. Aortic rings were exposed to cumulative concentrations of UK-14304 (10-9-10-5 M) in the presence of increasing concentrations of the PKC inhibitors chelerythrine chloride (5 and 10 µM) or calphostin C (0.1 and 0.5 µM). Both inhibitors significantly attenuated the contraction to UK-14304 in both NR and LHR aorta (Fig. 3), suggesting that PKC contributes to the alpha 2-AR contraction. PKC activity assays performed on cytosolic and membrane fractions of aortic homogenates confirmed that PKC is translocated from the cytosol to the membrane after UK-14304 stimulation. However, UK-14304 stimulation of PKC activity was not greater in LHR homogenates than in NR homogenates (Fig. 4A).


View larger version (32K):
[in this window]
[in a new window]
  		Fig. 3.   The PKC inhibitors chelerythrine chloride and calphostin C attenuate UK-14304 contraction. Treatment of NR (A and C) and LHR (B and D) endothelium-denuded aortic rings with chelerythrine chloride (1 and 10 µM; A and B) and calphostin C (0.1 and 0.5 µM; C and D) significantly and concentration-dependently attenuated contraction to the alpha 2-AR agonist UK-14304 (10-9-10-5 M). * Statistically significant difference between vehicle and treatment; n = 7.



View larger version (21K):
[in this window]
[in a new window]
  		Fig. 4.   UK-14304 translocates PKC activity to the membrane fraction. More [32P]ATP was incorporated in a PKC-specific substrate by the membrane fraction of aortic homogenates treated with the alpha 2-AR agonist UK-14304 (10 µM) than in basal homogenates (A; n = 5). Similarly, Western blots show more PKC-delta in the membrane fraction of NR aortic homogenates after UK-14304 exposure (B; n = 3). Representative blots are shown in C. cyt, Cytosolic; mem, membrane. * Statistically significant difference between vehicle and treatment.

Both chelerythrine and calphostin are non-isoform-specific inhibitors of PKC. To evaluate whether a calcium-independent PKC isoform is activated after alpha 2-AR stimulation, Western blot analysis of PKC-delta in membrane and cytosolic aortic homogenate fractions was performed. PKC-delta expression was similar in LHR and NR aorta (ratio of membrane to cytosolic PKC-delta : NR, 2.19 ± 0.55; LHR, 1.93 ± 0.34); however, UK-14304 (10 µM) translocated PKC-delta from the cytosolic fraction to the membrane fraction in NR aorta only (Fig. 4, B and C). This suggests that PKC-delta is normally activated by alpha 2-AR, but not in chronic NOS inhibition hypertension. Together, these data suggest that PKC plays a large role in alpha 2-AR contraction in both NR and LHR aorta. Furthermore, although total PKC activity after UK-14304 stimulation is not different between NR and LHR, the isoform of PKC contributing to alpha 2-AR contraction may differ between NR and LHR aorta.

To evaluate the role of PKC in alpha 2-AR-stimulated and basal calcium sensitivity, ionomycin-permeabilized aortic rings in the presence of chelerythrine (10 µM) or vehicle (DMSO) were exposed to CaCl2 (0.8 mM). After the contraction plateaued, cumulative concentrations of UK-14304 (10-8-10-5 M) were added to the bath. LHR aorta contracted more to CaCl2 than did NR aorta. However, chelerythrine attenuated only LHR CaCl2 contraction, so that in the presence of chelerythrine, the CaCl2 contractions were no longer different (Fig. 5A). Chelerythrine attenuated contraction to UK-14304 similarly in NR and LHR ionomycin-permeabilized aortic rings (Fig. 5B). These results suggest that PKC contributes to alpha 2-AR-stimulated calcium sensitivity in both NR and LHR aorta but basal augmentation of calcium sensitivity in LHR aorta may be due to enhanced PKC activity.


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 5.   The PKC inhibitor chelerythrine chloride attenuates contraction to CaCl2 in LHR only and the alpha 2-AR agonist UK-14304 in both LHR and NR ionomycin-permeabilized aortic rings. Endothelium-denuded aortic rings in calcium-free buffer were permeabilized with the calcium ionophore ionomycin (1.5 µM) in the presence of chelerythrine chloride (10 µM) or vehicle. CaCl2 (0.8 mM) was added to the bath, and the contraction was allowed to plateau (A). Rings were then exposed to cumulative concentrations of UK-14304 (10-8-10-5 M; B). The presence of chelerythrine abolished augmented contraction to CaCl2 in LHR aorta. * Statistically significant difference between vehicle and treatment; #statistically significant difference between NR and LHR; n = 5.

Contribution of calcium-dependent PKC to alpha 2-AR contraction. To determine whether an additional PKC isoform was recruited during alpha 2-AR contraction in LHR aorta, rings were exposed to cumulative concentrations of UK-14304 in the presence of the calcium-dependent PKC inhibitor Gö-6976 (0.1 or 1 µM) or vehicle. Gö-6976 attenuated contraction to UK-14304 only in LHR aorta and not in NR aorta (Fig. 6). Similarly, Western blot analysis showed that PKC-alpha is translocated to the membrane after UK-14304 (10 µM) stimulation in LHR aortic homogenates only (Fig. 7), suggesting that PKC-alpha is only activated by alpha 2-AR in LHR aorta. However, PKC-alpha expression was similar in NR and LHR aorta (ratio of membrane to cytosolic PKC-alpha : NR, 1.91 ± 0.11; LHR, 2.38 ± 0.26).


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 6.   The calcium-dependent PKC inhibitor Gö-6976 attenuates UK-14304 contraction in LHR aortic rings only. Treatment of NR (A) and LHR (B) endothelium-denuded aortic rings with Gö-6976 (0.1 and 1 µM) significantly attenuated contraction to the alpha 2-AR agonist UK-14304 (10-9-10-5 M) in LHR rings only. * Statistically significant difference between vehicle and treatment; n = 7.



View larger version (37K):
[in this window]
[in a new window]
  		Fig. 7.   The alpha 2-AR agonist UK-1430 translocates PKC-alpha to the membrane only in LHR aorta. A: membrane and cytosolic fractions of aortic homogenates in the presence and absence of UK-14304 (10 µM) were subjected to Western blot analysis and probed for PKC-alpha . More PKC-alpha is present in the membrane fraction of LHR aortic homogenates after UK-14304 stimulation, indicating translocation to the membrane. Data are shown as the ratio of membrane to cytosolic PKC-alpha . Representative blots are shown in B. * Statistically significant difference between basal and UK-14304 treated; n = 5.

To evaluate the role that calcium-dependent PKC plays in basal and alpha 2-AR-stimulated calcium sensitivity, ionomycin-permeabilized aortic rings in the presence of Gö-6976 (1 µM) or vehicle were exposed to 0.4 mM CaCl2. After contraction plateaued, rings were exposed to cumulative concentrations of UK-14304 (10-8-10-5 M). Gö-6976 attenuated the contraction to CaCl2 and the cumulative contraction to UK-14304 in LHR aorta and not in NR aorta (Fig. 8, A and B), so that contractions to CaCl2 and UK-14304 in NR and LHR aorta were not different in the presence of Gö-6976. These data suggest that calcium-dependent PKC augments basal and alpha 2-AR-stimulated calcium sensitivity in LHR aorta.


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 8.   The calcium-dependent PKC inhibitor Gö-6976 attenuates contraction to CaCl2 and the alpha 2-AR agonist UK-14304 in ionomycin-permeabilized LHR aortic rings only. Endothelium-denuded aortic rings in calcium-free buffer were permeabilized with the calcium ionophore ionomycin (1.5 µM) in the presence of Gö-6976 (1 µM) or vehicle. CaCl2 (0.4 mM) was added to the bath, and the contraction was allowed to plateau (A). Rings were then exposed to cumulative concentrations of UK-14304 (10-8-10-5 M; B). The presence of Gö-6976 abolished augmented contraction to CaCl2 and UK-14304 in LHR aorta. * Statistically significant difference between vehicle and treatment; n = 5.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS AND MATERIALS
RESULTS
DISCUSSION
REFERENCES

The goal of this study was to evaluate enhanced PKC activity as a potential cause of augmented alpha 2-AR reactivity in aorta from chronic NOS-inhibited hypertensive rats. We observed that, in addition to enhanced alpha 2-AR contractile sensitivity, LHR aorta have increased basal and alpha 2-AR-stimulated calcium sensitivity. This increase in calcium sensitivity may in fact be an underlying mechanism for augmented alpha 2-AR contractility, although decreased sarcoplasmic reticulum buffering capacity in LHR arteries cannot be excluded as a mechanism. PKC has been shown to affect both calcium entry (4, 24) and calcium sensitivity (5, 8, 9, 11, 25). Therefore, we sought to evaluate the contribution of PKC to alpha 2-AR contraction. We found that two separate inhibitors of PKC, calphostin C and chelerythrine chloride, significantly attenuated alpha 2-AR contraction in NR and LHR aorta and noted that PKC-delta is translocated to the membrane fraction of aortic homogenates after alpha 2-AR stimulation in NR aorta. Together, these data extend previous suggestions that PKC participates in alpha 2-AR contraction in normotensive rat aorta and suggest that a Ca2+-independent isoform of PKC, PKC-delta , is activated after alpha 2-AR stimulation and may mediate contraction in normotensive rat aorta. However, although PKC contributes to alpha 2-AR contraction in LHR aorta, these data also suggest that PKC-delta does not mediate this contraction and that a change in PKC isoform occurs with NOS inhibition hypertension.

Interestingly, chelerythrine significantly attenuated alpha 2-AR-stimulated calcium sensitivity in both NR and LHR, but only reduced basal calcium sensitivity in LHR aorta. This suggests that alpha 2-AR contraction augments calcium sensitivity via receptor-stimulated PKC activity. Several other studies showed that calcium sensitivity is augmented in hypertension (28, 29) and suggested that PKC may play a role in this (3, 23, 29, 32). Data presented here confirm those studies. Chelerythrine attenuated contraction to CaCl2 in LHR aorta only, suggesting that PKC, at least in part, is responsible for augmented basal calcium sensitivity in LHR in the absence of receptor stimulation.

Kanashiro et al. (15) reported that phorbol 12,13-dibutyrate and phenylephrine stimulate translocation of PKC-alpha to the membrane fraction in aortic homogenates from virgin female rats, but this translocation is abolished in pregnant rats. Treatment with NG-nitro-L-arginine methyl ester restored PDBu and phenylephrine translocation of PKC-alpha . Similarly, we show that chronic L-NNA treatment recruits PKC-alpha .

The calcium-dependent PKC inhibitor Gö-6976 attenuated alpha 2-AR contraction in LHR aorta, but not in NR aorta, suggesting that NOS inhibition hypertension results in the recruitment of a Ca2+-dependent PKC isoform to the alpha 2-AR contractile pathway. Additionally, Western blot analysis demonstrated that PKC-alpha was translocated to the membrane fraction of LHR but not NR aorta after alpha 2-AR stimulation, suggesting that PKC-alpha mediates alpha 2-AR contraction in LHR aorta. This PKC isoform may also contribute to basal and alpha 2-AR-stimulated calcium sensitivity in LHR aorta but not in NR aorta. Therefore, the translocation of PKC-alpha to the membrane fraction after alpha 2-AR stimulation in LHR aorta and not in NR aorta further suggests that PKC-alpha is recruited to the alpha 2-AR signal transduction cascade after chronic NOS inhibition hypertension to augment vasoreactivity by increasing calcium sensitivity.

The PKC activity data suggest a tendency for increased basal PKC activity in LHR, but this did not reach significance. It is possible that the assay was not sensitive enough to detect small changes in activity without isoform-specific assays. Therefore, without a more sensitive, isoform-specific PKC assay it cannot be concluded that PKC activity is elevated in LHR aorta at baseline.

Together, these data suggest that in NOS inhibition hypertension there is a switching of the PKC isoform participating in alpha 2-AR contraction from Ca2+ independent to Ca2+ dependent. Increased pressure or hypertrophy could precipitate the isoform change (9, 16). This change in isoform appears to meditate the increase in alpha 2-AR-stimulated calcium sensitivity as well as alpha 2-AR vasoreactivity. However, we did not examine the role of other PKC isoforms, and one or more of these isoforms may also be involved. Future studies should investigate these other PKC isoforms to more fully understand the alpha 2-AR contractile pathway and changes that occur with hypertension. Additionally, the contribution of PKC-alpha to vasoconstriction in hypertension and to other contractile pathways is unknown and will be tested in future experiments.

Upstream activation of PKC also remains an open question. Previous studies suggest that PLC activation is an unlikely mediator because inositol 1,4,5-trisphosphate production is not increased after alpha 2-AR stimulation (20) and intracellular calcium release contributes minimally to alpha 2-AR contraction (20, 23). It is possible that PLD releases diacylglycerol to activate PKC, as suggested by Deth and co-workers (1). However, these earlier studies relied on wortmannin as a specific PLD inhibitor. More recently, wortmannin has also been found to be an effective inhibitor of myosin light chain kinase and phosphatidylinositol 3-kinase (PI3K) (24, 35). This is especially troublesome because several studies have demonstrated that PI3K can activate PKC either through the production of 3,4,5-inositol trisphosphate or through phosphorylation of the PKC molecule (6, 18, 31, 34). Preliminary studies in our lab have shown that the PI3K inhibitor LY-294002 significantly attenuates alpha 2-AR contraction in both NR and LHR aorta (unpublished observations). Future experiments will review the ability of PI3K to activate PKC in this pathway.

In conclusion, this study provides novel evidence that the mechanism of augmented alpha 2-AR contractile reactivity after chronic NOS inhibition hypertension is due, at least in part, to a PKC-dependent increase in basal and receptor-stimulated calcium sensitivity. Moreover, NOS inhibition hypertension recruits a calcium-dependent PKC isoform, most likely PKC-alpha , to the alpha 2-AR contractile pathway. It will be important for future studies to determine whether PKC contributes to induction or maintenance of NOS-deficient hypertension.


    ACKNOWLEDGEMENTS

The authors express special thanks to Pam Allgood for expert technical assistance.


    FOOTNOTES

This work was supported by an Atorvastatin Research Award and National Heart, Lung, and Blood Institute Grant HL-03852.

Address for reprint requests and other correspondence: R. W. Carter, 915 Camino de Salud, Vascular Physiology Research Division, Dept. of Cell Biology and Physiology, Univ. of New Mexico Health Sciences Center, Albuquerque, NM 87131-5218 (E-mail: bcarter{at}salud.unm.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

First published September 19, 2002;10.1152/ajpheart.00453.2002

Received 29 May 2002; accepted in final form 9 September 2002.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS AND MATERIALS
RESULTS
DISCUSSION
REFERENCES

1.   Aburto, T, Jinsi A, Zhu Q, and Deth RC. Involvement of protein kinase C activation in alpha 2-adrenoceptor-mediated contractions of rabbit saphenous vein. Eur J Pharmacol 277: 35-44, 1995[ISI][Medline].

2.   Angus, JA, Cocks TM, and Satoh K. The alpha  adrenoceptors on endothelial cells. Fed Proc 45: 2355-2359, 1986[ISI][Medline].

3.   Bazan, E, Campbell AK, and Rapoport RM. Protein kinase C activity in blood vessels from normotensive and spontaneously hypertensive rats. Eur J Pharmacol 227: 343-348, 1992[ISI][Medline].

4.   Boixel, C, Tessier S, Pansard Y, Lang-Lazdunski L, Mercadier JJ, and Hatem SN. Tyrosine kinase and protein kinase C regulate L-type Ca2+ current cooperatively in human atrial myocytes. Am J Physiol Heart Circ Physiol 278: H670-H676, 2000[Abstract/Free Full Text].

5.   Buus, CL, Aalkjaer C, Nilsson H, Juul B, Moller JV, and Mulvany MJ. Mechanisms of Ca2+ sensitization of force production by noradrenaline in rat mesenteric small arteries. J Physiol 510: 577-590, 1998[Abstract/Free Full Text].

6.   Carpenter, CL, and Cantley LC. Phosphoinositide 3-kinase and the regulation of cell growth. Biochim Biophys Acta 1288: M11-M16, 1996[Medline].

7.   Carter, RW, and Kanagy NL. Tyrosine kinases regulate intracellular calcium during alpha 2-adrenergic contraction in rat aorta. Am J Physiol Heart Circ Physiol 283: H1673-H1680, 2002[Abstract/Free Full Text].

8.   Eto, M, Kitazawa T, Yazawa M, Mukai H, Ono Y, and Brautigan DL. Histamine-induced vasoconstriction involves phosphorylation of a specific inhibitor protein for myosin phosphatase by protein kinase C alpha  and delta  isoforms. J Biol Chem 276: 29072-29078, 2001[Abstract/Free Full Text].

9.   Gu, X, and Bishop SP. Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat. Circ Res 75: 926-931, 1994[Abstract/Free Full Text].

10.   Herbert, JM, Augereau JM, Gleye J, and Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 172: 993-999, 1990[ISI][Medline].

11.   Hori, M, Sato K, Miyamoto S, Ozaki H, and Karaki H. Different pathways of calcium sensitization activated by receptor agonists and phorbol esters in vascular smooth muscle. Br J Pharmacol 110: 1527-1531, 1993[ISI][Medline].

12.   Ikebe, M, and Brozovich FV. Protein kinase C increases force and slows relaxation in smooth muscle: evidence for regulation of the myosin light chain phosphatase. Biochem Biophys Res Commun 225: 370-376, 1996[ISI][Medline].

13.   Jinsi, A, and Deth RC. alpha 2-Adrenoceptor-mediated vasoconstriction requires a tyrosine kinase. Eur J Pharmacol 277: 29-34, 1995[ISI][Medline].

14.   Kanagy, NL. Increased vascular responsiveness to alpha 2-adrenergic stimulation during NOS inhibition-induced hypertension. Am J Physiol Heart Circ Physiol 273: H2756-H2764, 1997[Abstract/Free Full Text].

15.   Kanashiro, CA, Cockrell KL, Alexander BT, Granger JP, and Khalil RA. Pregnancy-associated reduction in vascular protein kinase C activity rebounds during inhibition of NO synthesis. Am J Physiol Regul Integr Comp Physiol 278: R295-R303, 2000[Abstract/Free Full Text].

16.   Kim, L, Lee T, Fu J, and Ritchie ME. Characterization of MAP kinase and PKC isoform and effect of ACE inhibition in hypertrophy in vivo. Am J Physiol Heart Circ Physiol 277: H1808-H1816, 1999[Abstract/Free Full Text].

17.   Kobayashi, E, Ando K, Nakano H, Iida T, Ohno H, Morimoto M, and Tamaoki T. Calphostins (UCN-1028), novel and specific inhibitors of protein kinase C. I. Fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 42: 1470-1474, 1989[Medline].

18.   Le Good, JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, and Parker PJ. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281: 2042-2045, 1998[Abstract/Free Full Text].

19.   Maasch, C, Wagner S, Lindschau C, Alexander G, Buchner K, Gollasch M, Luft FC, and Haller H. Protein kinase C alpha  targeting is regulated by temporal and spatial changes in intracellular free calcium concentration [Ca2+]i. FASEB J 14: 1653-1663, 2000[Abstract/Free Full Text].

20.   Macrez-Lepretre, N, Morel JL, and Mironneau J. Effects of phospholipase C inhibitors on Ca2+ channel stimulation and Ca2+ release from intracellular stores evoked by alpha 1A- and alpha 2A-adrenoceptors in rat portal vein myocytes. Biochem Biophys Res Commun 218: 30-34, 1996[ISI][Medline].

21.   Martiny-Baron, G, Kananietz MG, Mischak H, Blumberg PM, Kochs G, Hugs H, Marme D, and Schachtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 268: 9194-9197, 1993[Abstract/Free Full Text].

22.   Morgan, KG, and Leinweber BD. PKC-dependent signalling mechanisms in differentiated smooth muscle. Acta Physiol Scand 164: 495-505, 1998[ISI][Medline].

23.   Mukundan, H, and Kanagy NL. Ca2+ influx mediates enhanced alpha 2-adrenergic contraction in aortas from rats treated with NOS inhibitor. Am J Physiol Heart Circ Physiol 281: H2233-H2240, 2001[Abstract/Free Full Text].

24.   Nakanishi, S, Kakita S, Takahashi I, Kawahara K, Tsukuda E, Sano T, Yamada K, Yoshida M, Kase H, and Matsuda Y. Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem 267: 2157-2163, 1992[Abstract/Free Full Text].

25.   Obejero-Paz, CA, Auslender M, and Scarpa A. PKC activity modulates availability and long openings of L-type Ca2+ channels in A7r5 cells. Am J Physiol Cell Physiol 275: C535-C543, 1998[Abstract/Free Full Text].

26.   Ruegg, JC. Smooth muscle: PKC-induced Ca2+ sensitisation by myosin phosphatase inhibition. J Physiol 520: 3, 1999[Abstract/Free Full Text].

27.   Sasajima, H, Shima H, Toyoda Y, Kimura K, Yoshikawa A, Hano T, and Nishio I. Increased Ca2+ sensitivity of contractile elements via protein kinase C in alpha -toxin permeabilized SMA from young spontaneously hypertensive rats. Cardiovasc Res 36: 86-91, 1997[Abstract/Free Full Text].

28.   Sato, A, Hattori Y, Sasaki M, Tomita F, Kohya T, Kitabatake A, and Kanno M. Agonist-dependent difference in the mechanisms involved in Ca2+ sensitization of smooth muscle of porcine coronary artery. J Cardiovasc Pharmacol 35: 814-821, 2000[ISI][Medline].

29.   Satoh, S, Kreutz R, Wilm C, Ganten D, and Pfitzer G. Augmented agonist-induced Ca2+-sensitization of coronary artery contraction in genetically hypertensive rats. Evidence for altered signal transduction in the coronary smooth muscle cells. J Clin Invest 94: 1397-1403, 1994[ISI][Medline].

30.   Silver, PJ, Cumiskey WR, and Harris AL. Vascular protein kinase C in Wistar-Kyoto and spontaneously hypertensive rats. Eur J Pharmacol 212: 143-149, 1992[ISI][Medline].

31.   Singh, SS, Chauhan A, Brockerhoff H, and Chauhan VP. Activation of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. Biochem Biophys Res Commun 195: 104-112, 1993[ISI][Medline].

32.   Soloviev, AI, and Bershtein SA. The contractile apparatus in vascular smooth muscle cells of spontaneously hypertensive rats possess increased calcium sensitivity: the possible role of protein kinase C. J Hypertens 10: 131-136, 1992[ISI][Medline].

33.   Su, X, Wang P, Ibitayo A, and Bitar KN. Differential activation of phosphoinositide 3-kinase by endothelin and ceramide in colonic smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 276: G853-G861, 1999[Abstract/Free Full Text].

34.   Toker, A, Meyer M, Reddy KK, Falck JR, Aneja R, Aneja S, Parra A, Burns DJ, Ballas LM, and Cantley LC. Activation of protein kinase C family members by the novel polyphosphoinositides PtdIns-3,4-P2 and PtdIns-3,4,5-P3. J Biol Chem 269: 32358-32367, 1994[Abstract/Free Full Text].

35.   Ui, M, Okada T, Hazeki K, and Hazeki O. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem Sci 20: 303-307, 1995[ISI][Medline].

36.   Viard, P, Exner T, Maier U, Mironneau J, Nurnberg B, and Macrez N. Gbeta gamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase. FASEB J 13: 685-694, 1999[Abstract/Free Full Text].

37.   Way, KJ, Chou E, and King GL. Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci 21: 181-187, 2000[Medline].

Am J Physiol Heart Circ Physiol 284(1):H309-H316
0363-6135/03 $5.00 Copyright © 2003 the American Physiological Society


This article has been cited by other articles:


Home page
 Am. J. Physiol. Cell Physiol.Home page
Y. Lu, H. Zhang, N. Gokina, M. Mandala, O. Sato, M. Ikebe, G. Osol, and S. A. Fisher
Uterine artery myosin phosphatase isoform switching and increased sensitivity to SNP in a rat L-NAME model of hypertension of pregnancy
Am J Physiol Cell Physiol, February 1, 2008; 294(2): C564 - C571.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
K. J. Allahdadi, L. C. Duling, B. R. Walker, and N. L. Kanagy
Eucapnic intermittent hypoxia augments endothelin-1 vasoconstriction in rats: role of PKC{delta}
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H920 - H927.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
K. J. Allahdadi, B. R. Walker, and N. L. Kanagy
ROK contribution to endothelin-mediated contraction in aorta and mesenteric arteries following intermittent hypoxia/hypercapnia in rats
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2911 - H2918.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
I. N. Bratz, G. M. Dick, L. D. Partridge, and N. L. Kanagy
Reduced molecular expression of K+ channel proteins in vascular smooth muscle from rats made hypertensive with N{omega}-nitro-L-arginine
Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1277 - H1283.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
I. N. Bratz, A. N. Swafford Jr., N. L. Kanagy, and G. M. Dick
Reduced functional expression of K+ channels in vascular smooth muscle cells from rats made hypertensive with N{omega}-nitro-L-arginine
Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1284 - H1290.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/1/H309    most recent
00453.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carter, R. W.
Right arrow Articles by Kanagy, N. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carter, R. W.
Right arrow Articles by Kanagy, N. L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH